UPDATE: Akebia to Present at the Credit Suisse 24t

CAMBRIDGE, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- In a release issued previously by Akebia Therapeutics, Inc. (NASDAQ: AKBA ), the company is updating the presentation time to 3:00 p.m. Mountain Time instead of 3:30 p.m. Mountain Time. The updated release follows:

Akebia Therapeutics, Inc. (NASDAQ: AKBA ), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that Jason A. Amello, Senior Vice President, Chief Financial Officer and Treasurer, will present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10, 2015 at 3:00 p.m. Mountain Time. The conference will take place at The Phoenician resort, in Scottsdale, Arizona.

Interested institutional investors that wish to schedule a meeting with management should contact Credit Suisse directly.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. The company has completed Phase 2 development of its lead product candidate, vadadustat, an oral therapy for the treatment of anemia related to CKD in both non-dialysis and dialysis patients.

Investors: Ed Joyce (617) 844-6130 Media: Argot Partners Eliza Schleifstein (917) 763-8106